Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247384 | 0.89 | BUB1 (0.33) | SYK | |
| SCHEMBL3244258 | 0.88 | HDAC4 (0.37) | HDAC4SYKOPRM1OPRL1 | |
| SCHEMBL3359227 | 0.86 | SYK (0.33) | SCN9ACYP3A4SCN10ASYK | |
| SCHEMBL3239041 | 0.78 | BACE1 (0.36) | SYKOPRM1OPRL1 | |
| SCHEMBL3357376 | 0.76 | CYP3A4 (0.32) | SCN9ACYP3A4SCN10A | |
| SCHEMBL3242322 | 0.75 | MEN1 (0.31) | — | |
| SCHEMBL3248773 | 0.75 | BACE1 (0.37) | SYKRXFP1 | |
| SCHEMBL3244383 | 0.74 | MEN1 (0.30) | — | |
| SCHEMBL3249132 | 0.69 | KDM1A (0.38) | SYKOPRL1 | |
| SCHEMBL3357636 | 0.67 | BACE1 (0.36) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | SCN9A 2804/4885CYP3A4 4679/4885SCN10A 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.